-
Je něco špatně v tomto záznamu ?
Lipoprotein(a) as a cardiovascular risk factor: current status
BG. Nordestgaard, MJ. Chapman, K. Ray, J. Borén, F. Andreotti, GF. Watts, H. Ginsberg, P. Amarenco, A. Catapano, OS. Descamps, E. Fisher, PT. Kovanen, JA. Kuivenhoven, P. Lesnik, L. Masana, Z. Reiner, MR. Taskinen, L. Tokgözoglu, A. Tybjærg-Hansen, . ,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu konsensus - konference, časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 1996 do Před 1 rokem
Open Access Digital Library
od 1996-01-01
PubMed
20965889
DOI
10.1093/eurheartj/ehq386
Knihovny.cz E-zdroje
- MeSH
- časná diagnóza MeSH
- hyperlipoproteinemie diagnóza genetika terapie MeSH
- imunoanalýza metody MeSH
- kardiovaskulární nemoci krev genetika prevence a kontrola MeSH
- koronární nemoc krev genetika prevence a kontrola MeSH
- lidé MeSH
- lipoprotein (a) krev genetika MeSH
- myši transgenní MeSH
- myši MeSH
- rizikové faktory MeSH
- sexuální faktory MeSH
- věkové faktory MeSH
- výběr pacientů MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- konsensus - konference MeSH
- práce podpořená grantem MeSH
AIMS: The aims of the study were, first, to critically evaluate lipoprotein(a) [Lp(a)] as a cardiovascular risk factor and, second, to advise on screening for elevated plasma Lp(a), on desirable levels, and on therapeutic strategies. METHODS AND RESULTS: The robust and specific association between elevated Lp(a) levels and increased cardiovascular disease (CVD)/coronary heart disease (CHD) risk, together with recent genetic findings, indicates that elevated Lp(a), like elevated LDL-cholesterol, is causally related to premature CVD/CHD. The association is continuous without a threshold or dependence on LDL- or non-HDL-cholesterol levels. Mechanistically, elevated Lp(a) levels may either induce a prothrombotic/anti-fibrinolytic effect as apolipoprotein(a) resembles both plasminogen and plasmin but has no fibrinolytic activity, or may accelerate atherosclerosis because, like LDL, the Lp(a) particle is cholesterol-rich, or both. We advise that Lp(a) be measured once, using an isoform-insensitive assay, in subjects at intermediate or high CVD/CHD risk with premature CVD, familial hypercholesterolaemia, a family history of premature CVD and/or elevated Lp(a), recurrent CVD despite statin treatment, ≥3% 10-year risk of fatal CVD according to European guidelines, and/or ≥10% 10-year risk of fatal + non-fatal CHD according to US guidelines. As a secondary priority after LDL-cholesterol reduction, we recommend a desirable level for Lp(a) <80th percentile (less than ∼50 mg/dL). Treatment should primarily be niacin 1-3 g/day, as a meta-analysis of randomized, controlled intervention trials demonstrates reduced CVD by niacin treatment. In extreme cases, LDL-apheresis is efficacious in removing Lp(a). CONCLUSION: We recommend screening for elevated Lp(a) in those at intermediate or high CVD/CHD risk, a desirable level <50 mg/dL as a function of global cardiovascular risk, and use of niacin for Lp(a) and CVD/CHD risk reduction.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12027952
- 003
- CZ-PrNML
- 005
- 20121207100822.0
- 007
- ta
- 008
- 120817e20101021enk f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1093/eurheartj/ehq386 $2 doi
- 035 __
- $a (PubMed)20965889
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Nordestgaard, Børge G $u Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, DK-2730 Herlev, Denmark. brno@heh.regionh.dk
- 245 10
- $a Lipoprotein(a) as a cardiovascular risk factor: current status / $c BG. Nordestgaard, MJ. Chapman, K. Ray, J. Borén, F. Andreotti, GF. Watts, H. Ginsberg, P. Amarenco, A. Catapano, OS. Descamps, E. Fisher, PT. Kovanen, JA. Kuivenhoven, P. Lesnik, L. Masana, Z. Reiner, MR. Taskinen, L. Tokgözoglu, A. Tybjærg-Hansen, . ,
- 520 9_
- $a AIMS: The aims of the study were, first, to critically evaluate lipoprotein(a) [Lp(a)] as a cardiovascular risk factor and, second, to advise on screening for elevated plasma Lp(a), on desirable levels, and on therapeutic strategies. METHODS AND RESULTS: The robust and specific association between elevated Lp(a) levels and increased cardiovascular disease (CVD)/coronary heart disease (CHD) risk, together with recent genetic findings, indicates that elevated Lp(a), like elevated LDL-cholesterol, is causally related to premature CVD/CHD. The association is continuous without a threshold or dependence on LDL- or non-HDL-cholesterol levels. Mechanistically, elevated Lp(a) levels may either induce a prothrombotic/anti-fibrinolytic effect as apolipoprotein(a) resembles both plasminogen and plasmin but has no fibrinolytic activity, or may accelerate atherosclerosis because, like LDL, the Lp(a) particle is cholesterol-rich, or both. We advise that Lp(a) be measured once, using an isoform-insensitive assay, in subjects at intermediate or high CVD/CHD risk with premature CVD, familial hypercholesterolaemia, a family history of premature CVD and/or elevated Lp(a), recurrent CVD despite statin treatment, ≥3% 10-year risk of fatal CVD according to European guidelines, and/or ≥10% 10-year risk of fatal + non-fatal CHD according to US guidelines. As a secondary priority after LDL-cholesterol reduction, we recommend a desirable level for Lp(a) <80th percentile (less than ∼50 mg/dL). Treatment should primarily be niacin 1-3 g/day, as a meta-analysis of randomized, controlled intervention trials demonstrates reduced CVD by niacin treatment. In extreme cases, LDL-apheresis is efficacious in removing Lp(a). CONCLUSION: We recommend screening for elevated Lp(a) in those at intermediate or high CVD/CHD risk, a desirable level <50 mg/dL as a function of global cardiovascular risk, and use of niacin for Lp(a) and CVD/CHD risk reduction.
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kardiovaskulární nemoci $x krev $x genetika $x prevence a kontrola $7 D002318
- 650 _2
- $a koronární nemoc $x krev $x genetika $x prevence a kontrola $7 D003327
- 650 _2
- $a časná diagnóza $7 D042241
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hyperlipoproteinemie $x diagnóza $x genetika $x terapie $7 D006951
- 650 _2
- $a imunoanalýza $x metody $7 D007118
- 650 _2
- $a lipoprotein (a) $x krev $x genetika $7 D017270
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši transgenní $7 D008822
- 650 _2
- $a výběr pacientů $7 D018579
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a sexuální faktory $7 D012737
- 655 _2
- $a konsensus - konference $7 D016446
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Chapman, M John
- 700 1_
- $a Ray, Kausik
- 700 1_
- $a Borén, Jan
- 700 1_
- $a Andreotti, Felicita $7 gn_A_00006518
- 700 1_
- $a Watts, Gerald F
- 700 1_
- $a Ginsberg, Henry
- 700 1_
- $a Amarenco, Pierre $7 gn_A_00005280
- 700 1_
- $a Catapano, Alberico
- 700 1_
- $a Descamps, Olivier S
- 700 1_
- $a Fisher, Edward
- 700 1_
- $a Kovanen, Petri T
- 700 1_
- $a Kuivenhoven, Jan Albert
- 700 1_
- $a Lesnik, Philippe
- 700 1_
- $a Masana, Luis
- 700 1_
- $a Reiner, Zeljko
- 700 1_
- $a Taskinen, Marja-Riitta
- 700 1_
- $a Tokgözoglu, Lale
- 700 1_
- $a Tybjærg-Hansen, Anne
- 700 1_
- $a ,
- 773 0_
- $w MED00009622 $t European heart journal $x 1522-9645 $g Roč. 31, č. 23 (20101021), s. 2844-53
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20965889 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20121207100856 $b ABA008
- 999 __
- $a ok $b bmc $g 949994 $s 785298
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 31 $c 23 $d 2844-53 $e 20101021 $i 1522-9645 $m European heart journal $n Eur Heart J $x MED00009622
- LZP __
- $a Pubmed-20120817/11/03